MHLW (Japan) approves Jardiance (empagliflozin) for the treatment of chronic kidney disease (CKD) – Nippon Boehringer Ingelheim

MHLW (Japan) approved on February 9 Nippon Boehringer Ingelheim’s SGLT2 inhibitor Jardiance (empagliflozin) for the treatment of chronic kidney disease (CKD) </p.

Jardiance has been available in Japan for the indication of type 2 diabetes and chronic heart failure. It is now newly approved for CKD, excluding patients with end-stage renal disease or those on dialysis.</p.

In the Japanese SGLT2 market, Jardiance will now be competing against AstraZeneca’s Forxiga (dapagliflozin), which already carries the same CKD indication. Mitsubishi Tanabe Pharma’s Canaglu (canagliflozin) is approved for CKD complicated with type 2 diabetes, while Astellas Pharma’s Suglat (ipragliflozin), Taisho Pharmaceutical’s Lusefi (luseogliflozin), and Kowa’s Deberza (tofogliflozin) do not have a CKD indication.